Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 820-826

  LaFleur, Michael D ^a   Lucumi, Edinson ^b   Napper, Andrew D ^b,c   Diamond, Scott L ^b   Lewis, Kim ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Alamarblue ; Clotrimazole; Drug resistance

Indexed keywords

CLOTRIMAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG POTENTIATION; FIBROBLAST; FUNGUS GROWTH; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; METABOLIC INHIBITION; MICROTITER PLATE ASSAY; MOLECULAR LIBRARY; NONHUMAN; THRUSH; VAGINITIS;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CELL ADHESION; CELL SURVIVAL; CLOTRIMAZOLE; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZINES; STAINING AND LABELING; XANTHENES;

EID: 79952792302     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq530     Document Type: Article

References (44)

1. Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab 2001; 20: 42-4.
2. Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 2000; 46: 397-403.
3. Kumamoto CA. Candida biofilms. Curr Opin Microbiol 2002; 5: 608-11.
4. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003; 11: 30-6.
5. Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004; 5: 186-97.
6. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofilms and drug resistance. Emerg Infect Dis 2004; 10: 14-9.
7. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-67.
8. Mukherjee PK, Chandra J. Candida biofilm resistance. Drug Resist Updat 2004; 7: 301-9.
9. Ramage G, Saville SP, Thomas DP et al. Candida biofilms: an update. Eukaryot Cell 2005; 4: 633-8.
10. Lopez-Ribot JL. Candida albicans biofilms: more than filamentation. Curr Biol 2005; 15: R453-5.
11. Mukherjee PK, Zhou G, Munyon R et al. Candida biofilm: a well-designed protected environment. Med Mycol 2005; 43: 191-208.
12. Kumamoto CA, Vinces MD. Alternative Candida albicans lifestyles: growth on surfaces. Annu Rev Microbiol 2005; 59: 113-33.
13. Zaoutis TE, Heydon K, Localio R et al. Outcomes attributable to neonatal candidiasis. Clin Infect Dis 2007; 44: 1187-93.
14. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002; 17: 168-75.
15. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 2006; 7: 495-504.
16. Ramage G, Bachmann S, Patterson TF et al. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49: 973-80.
17. Mukherjee PK, Chandra J, Kuhn DM et al. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 4333-40.
18. Niimi M, Firth NA, Cannon RD. Antifungal drug resistance of oral fungi. Odontology 2010; 98: 15-25.
19. Nett J, Lincoln L, Marchillo K et al. Putative role of β-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 2007; 51: 510-20.
20. Vediyappan G, Rossignol T, d'Enfert C. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to β-glucans. Antimicrob Agents Chemother 2010; 54: 2096-111.
21. Perumal P, Mekala S, Chaffin WL. Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother 2007; 51: 2454-63.
22. LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 2006; 50: 3839-46.
23. LaFleur MD, Qi Q, Lewis K. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother 2010; 54: 39-44.
24. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2006; 55: 1-94.
25. Skiest DJ, Vazquez JA, Anstead GM et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44: 607-14.
26. Sobel JD, Wiesenfeld HC, Martens M et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351: 876-83.
27. Sobel JD, Ferris D, Schwebke J et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006; 194: 1283-9.
28. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 2000; 1: 47-59.
29. Coates AR, Hu Y. New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. Drugs R D 2006; 7: 133-51.
30. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007; 5: 48-56.
31. Hoyle BD, Jass J, Costerton JW. The biofilm glycocalyx as a resistance factor. J Antimicrob Chemother 1990; 26: 1-5.
32. von Eiff C, Heilmann C, Peters G. New aspects in the molecular basis of polymer-associated infections due to staphylococci. Eur J Clin Microbiol Infect Dis 1999; 18: 843-6.
33. Ramage G, Vande Walle K, Wickes BL et al. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-9.
34. Harriott MM, Lilly EA, Rodriguez TE et al. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 2010; 156: 3635-44.
35. Dongari-Bagtzoglou A, Kashleva H, Dwivedi P et al. Characterization of mucosal Candida albicans biofilms. PLoS One 2009; 4: e7967.
36. Hernaez ML, Gil C, Pla J et al. Induced expression of the Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast 1998; 14: 517-26.
37. Holmes AR, Lin YH, Niimi K et al. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob Agents Chemother 2008; 52: 3851-62.
38. Marques SM, Esteves da Silva JC. Firefly bioluminescence: a mechanistic approach of luciferase catalyzed reactions. IUBMB Life 2009; 61: 6-17.
39. Bryson HM, Fulton B, Benfield P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 1996; 52: 549-63.
40. Bujdakova H, Kuchta T, Sidoova E et al. Anti-Candida activity of four antifungal benzothiazoles. FEMS Microbiol Lett 1993; 112: 329-33.
41. Fabry S, Gaborova S, Bujdakova H et al. Inhibition of germ tube formation, filamentation and ergosterol biosynthesis in Candida albicans treated with 6-amino-2-n-pentylthiobenzothiazole. Folia Microbiol (Praha) 1999; 44: 523-6.
42. Sanglard D, Ischer F, Marchetti O et al. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol 2003; 48: 959-76.
43. Cowen LE. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog 2009; 5: e1000471.
44. Lamping E, Monk BC, Niimi K et al. Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell 2007; 6: 1150-65.